文献速递妇科

卵巢癌与宫颈癌患者铂类超敏反应的临床分析

[Clinical analysis of hypersensitivity reaction of platinum in ovarian cancer and cervical cancer patients].
PubMed 文献 · Zhonghua Fu Chan Ke Za Zhi · 2016-01-01

研究分析北京协和医院2013年1月至2016年1月收治的860例上皮性卵巢癌(卡铂/紫杉醇每3周方案)和580例宫颈癌(顺铂每周同步放化疗)患者,铂类超敏反应发生率分别为8.8%(76/860)和5.9%(34/580),多为1-2级,最常见症状为胸闷和呼吸困难。卵巢癌超敏反应危险因素包括复发及化疗疗程数增多,超敏反应对无进展生存无影响。

要点

  • 卵巢癌铂类超敏反应发生率8.8%(76/860),宫颈癌5.9%(34/580)。
  • 超敏反应多为1-2级:卵巢癌78.9%(60/76),宫颈癌82.4%(28/34)。
  • 卵巢癌超敏反应危险因素包括复发(P=0.010)及化疗疗程数增多(均P<0.05)。

核心结论

  • 在接受卡铂治疗的卵巢癌患者和接受顺铂同步放化疗的宫颈癌患者中,铂类超敏反应大多轻微且结局良好;复发和较长化疗疗程是上皮性卵巢癌卡铂超敏反应的危险因素。

研究设计与样本

  • 回顾性分析北京协和医院2013年1月至2016年1月收治的上皮性卵巢癌(卡铂/紫杉醇每3周)和宫颈癌(顺铂每周同步放化疗)患者资料。
  • 共纳入卵巢癌860例、宫颈癌580例,分析一般特征、病理特征、治疗及预后,以确定超敏反应的严重程度、症状、结局及危险因素。

主要发现

  • 卵巢癌超敏反应发生率为8.8%(76/860),宫颈癌为5.9%(34/580)。
  • 卵巢癌超敏反应中1级7例、2级53例,1-2级占78.9%(60/76);宫颈癌中1级11例、2级17例,1-2级占82.4%(28/34)。
  • 超敏反应多发生于铂类静脉输注过程中:卵巢癌98.7%(75/76),宫颈癌97.1%(33/34)。
  • 卵巢癌最常见症状为胸闷和呼吸困难(92.1%,70/76),其次为皮肤反应(53.9%,41/76);宫颈癌最常见症状为胸闷和呼吸困难(97.1%,33/34),其次为皮肤反应(88.2%,30/34)。
  • 卵巢癌超敏反应危险因素包括复发(P=0.010)、初治患者化疗达7或9个疗程及复发患者化疗达6或7个疗程(均P<0.05);宫颈癌患者未发现显著危险因素(均P>0.05)。

关键数值与推荐

  • 卵巢癌超敏反应后不同处理组间超敏反应再发率无显著差异(χ2=0.517,P=0.915):沿用原化疗方案4例中1例再发,脱敏治疗13例中4例再发,分离药物11例中3例再发,换用顺铂11例中2例再发。
  • 宫颈癌超敏反应后不同处理组间超敏反应再发率无显著差异(χ2=0.079,P=1.000):沿用原化疗方案9例中2例再发,脱敏治疗17例中3例再发。
  • 超敏反应对卵巢癌无进展生存无影响(P=0.144),对宫颈癌无进展生存亦无影响(P=0.782)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the incidence, risk factors, management and prognosis of hypersensitivity reaction (HSR) of platinum-based chemotherapy in patients of ovarian cancer and cervical cancer. Methods: Cases from Peking Union Medical College Hospital from Jan. 2013 to Jan. 2016 were checked for patients' data of epithelial ovarian cancer treated with carboplatin/paclitaxel (every 3 weeks) and patients of cervical cancer treated with concurrent radiochemotherapy using cisplatin (every week). General characters, pathological features, treatment and prognosis of patients were analyzed to determine the severity, symptoms, outcomes and risk factors of HSR. Results: (1) Prevalence of HSR: there were 860 cases of ovarian cancer and 580 cases of cervical cancer, among which HSR occurred in 8.8% (76/860) and 5.9% (34/580) patients, respectively. (2) Grading for HSR: most HSR were grade 1 or 2, with 78.9%(60/76) in ovarian cancer and 82.4%(28/34) in cervical cancer patients. In ovarian cancer patients, there were 7 cases of grade 1 HSR and 53 cases of grade 2 HSR, and in cervical cancer patients, there were 11 cases of grade 1 HSR and 17 cases of grade 2 HSR. (3) Symptoms of HSR: most of HSR happened during intravenous infusion of platinum agents, with 98.7% (75/76) in ovarian cancer and 97.1% (33/34) in cervical cancer patients. In ovarian and cervical cancer patients, most common symptom were tight chest and dyspnea, which happened in 92.1% (70/76) and 97.1% (33/34) patients, respectively. Secondary common symptom were skin reactions, which happened in 53.9% (41/76) and 88.2% (30/34) patients respectively. (4) Treatment after HSR: of 76 ovarian cancer cases with HSR, there were no significant difference in the ratio of HSR recurrence among patients of different treatment after HSR (χ2=0.517, P=0.915): 1 of 4 patients applying prior chemotherapy, 4 of 13 cases receiving desensitization, 3 of 11 cases separating medicine, 2 of 11 patients switching to cisplatin. In 34 cervical cancer cases of HSR, there were also no significant difference in the ratio of HSR recurrence among patients of different treatment after HSR (χ2=0.079, P=1.000): 2 of 9 patients applying prior chemotherapy, 3 of 17 cases receiving desensitization. (5) Risk factors of HSR and patients prognosis: in ovarian cancer patients of HSR, risk factors included relapse (P=0.010), courses of chemotherapy reaching seven or nine for patients of primary treatment or reaching six or seven for recurrent patients (all P<0.05). There were no significant risk factors for cervical cancer patients of HSR (all P>0.05). HSR had no impact on the progression- free survival for ovarian cancer (P=0.144) or cervical cancer (P=0.782). Conclusions: In ovarian cancer patients treated with carboplatin and cervical cancer patients treated with concurrent radiochemotherapy using cisplatin, most HSR of platinum are mild and favorable outcomes. Relapse and longer chemotherapy courses are risk factors for HSR of carboplatin for epithelial ovarian cancer.

来源:Zhonghua Fu Chan Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Li L, Wu M, Yang JX, et al. [Clinical analysis of hypersensitivity reaction of platinum in ovarian cancer and cervical cancer patients]. Zhonghua Fu Chan Ke Za Zhi. 2016. PMID: 27916065. doi:10.3760/cma.j.issn.0529-567X.2016.11.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。